Physiomics (GB:PYC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Physiomics plc, a leader in mathematical modelling, has secured a £157k contract with a major pharmaceutical client to enhance dosing and scheduling decisions for a novel cancer therapy. This project marks the company’s first use of Antibody-Drug Conjugates in their Virtual Tumour platform, positioning Physiomics at the cutting edge of oncology drug development. The collaboration underscores the ongoing trust in Physiomics’ expertise in advanced therapeutic modelling.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.